Published in Antimicrob Agents Chemother on May 01, 2005
Pyrophosphorolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2007) 1.03
The "Connection" Between HIV Drug Resistance and RNase H. Viruses (2010) 1.00
Mg2+ dependency of HIV-1 reverse transcription, inhibition by nucleoside analogues and resistance. Nucleic Acids Res (2006) 0.96
AZT resistance of simian foamy virus reverse transcriptase is based on the excision of AZTMP in the presence of ATP. Nucleic Acids Res (2007) 0.95
HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors. J Virol (2012) 0.92
NTP-mediated nucleotide excision activity of hepatitis C virus RNA-dependent RNA polymerase. Proc Natl Acad Sci U S A (2013) 0.86
The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance. Viruses (2010) 0.85
HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection. PLoS Comput Biol (2012) 0.83
Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants. Antimicrob Agents Chemother (2006) 0.81
Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer. J Biol Chem (2013) 0.81
Utilization of a deoxynucleoside diphosphate substrate by HIV reverse transcriptase. PLoS One (2008) 0.80
Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase. Antimicrob Agents Chemother (2015) 0.77
Modulating the DNA polymerase β reaction equilibrium to dissect the reverse reaction. Nat Chem Biol (2017) 0.75
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Physiological concentrations of purines and pyrimidines. Mol Cell Biochem (1994) 6.95
Visualization of the intracellular behavior of HIV in living cells. J Cell Biol (2002) 6.59
A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell (1999) 3.67
Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol (2001) 3.66
Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry (1998) 3.59
Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci U S A (1998) 3.31
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
Comparison of methods for extraction of bacterial adenine nucleotides determined by firefly assay. Appl Microbiol (1975) 3.18
Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol (2001) 2.95
Phosphotransfer networks and cellular energetics. J Exp Biol (2003) 2.79
Quantitative extraction and estimation of intracellular nucleoside triphosphates of Escherichia coli. Anal Biochem (1972) 2.48
Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol (2001) 2.36
A novel method for measurement of submembrane ATP concentration. J Biol Chem (2000) 1.92
Macrophages and the human immunodeficiency virus. Immunol Today (1990) 1.90
Characteristics of human mononuclear phagocytes. Blood (1979) 1.88
The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol (2000) 1.84
Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways. J Gene Med (2002) 1.58
Secretable storage pools in platelets. Annu Rev Med (1979) 1.49
Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother (2000) 1.49
Analysis of nucleotide pools in animal cells. Methods Cell Biol (1973) 1.41
Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J (2000) 1.40
Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J Virol (2002) 1.36
Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry (2003) 1.32
Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. Antivir Ther (2001) 1.30
Detection of activities that interfere with the enzymatic assay of deoxyribonucleoside 5'-triphosphates. J Biol Chem (1980) 1.30
Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes. J Virol (2003) 1.27
Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2002) 1.25
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2002) 1.23
Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol (2001) 1.20
Metabolism of inorganic pyrophosphate (PPi). Arthritis Rheum (1976) 1.17
Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer. J Biol Chem (1998) 1.14
Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem (2002) 1.13
Inorganic pyrophosphate metabolism in arthritis. Rheum Dis Clin North Am (1988) 1.11
The influence of ribose 5-phosphate availability on purine synthesis of cultured human lymphoblasts and mitogen-stimulated lymphocytes. J Biol Chem (1984) 1.10
The concentration and control of cytoplasmic free inorganic pyrophosphate in rat liver in vivo. Biochem J (1974) 1.10
Luminescent immobilized enzyme test systems for inorganic pyrophosphate: assays using firefly luciferase and nicotinamide-mononucleotide adenylyl transferase or adenosine-5'-triphosphate sulfurylase. Anal Biochem (1991) 1.05
New insights into the bioenergetics of mitochondrial disorders using intracellular ATP reporters. Mol Biol Cell (2003) 1.02
Changes in activation markers and cell membrane receptors on human peripheral blood T lymphocytes during cell cycle progression after PHA stimulation. Immunology (1988) 0.97
A rapid, enzymatic assay for measurement of inorganic pyrophosphate in biological samples. Clin Chim Acta (1976) 0.96
Extraction of adenosine triphosphate from microbial and somatic cells. Methods Enzymol (1986) 0.94
Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids. Biochem Pharmacol (2000) 0.92
Enzymatic assay for quantification of deoxynucleoside triphosphates in human cells exposed to antiretroviral 2',3'-dideoxynucleosides. Anal Biochem (1994) 0.92
Extraction of adenine nucleotides from cultured endothelial cells. Anal Biochem (1986) 0.90
Identification of inorganic pyrophosphate in human platelets and its release on stimulation with thrombin. J Clin Invest (1973) 0.88
Lymphocyte blastogenesis studied by volume spectroscopy. Scand J Immunol (1979) 0.85
Comparison of extraction procedures for high-performance liquid chromatographic determination of cellular deoxynucleotides. J Chromatogr A (1994) 0.83
Chromatin structure and nucleic acid synthesis in human lymphocyte activation by phytohemagglutinin. Exp Cell Res (1984) 0.81
Inorganic pyrophosphate levels in blood platelets from normal donors and patients with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum (1983) 0.79
Importance of platelet-free preparations for evaluating lymphocyte nucleotide levels in inherited or acquired immunodeficiency syndromes. Clin Sci (Lond) (1983) 0.77
Regulation of S-adenosylmethionine synthetase activity in cultured human lymphocytes. Biochim Biophys Acta (1991) 0.76
Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2002) 1.25
Cytokine quantitation: technologies and applications. Front Biosci (2007) 1.13
Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase. J Biol Chem (2004) 1.08
Older age and plasma viral load in HIV-1 infection. AIDS (2004) 1.04
The influence of different types of alcoholic beverages on disrupting highly active antiretroviral treatment (HAART) outcome. Alcohol Alcohol (2009) 0.98
Stable complexes formed by HIV-1 reverse transcriptase at distinct positions on the primer-template controlled by binding deoxynucleoside triphosphates or foscarnet. J Mol Biol (2007) 0.93
A randomized controlled trial of Structural Ecosystems Therapy for HIV medication adherence and substance abuse relapse prevention. Drug Alcohol Depend (2010) 0.89
The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance. Viruses (2010) 0.85
Associations of cytokines, sleep patterns, and neurocognitive function in youth with HIV infection. Clin Immunol (2012) 0.84
Influence of CD4+ T cell counts on viral evolution in HIV-infected individuals undergoing suppressive HAART. Virology (2004) 0.82
Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. J Neurovirol (2006) 0.81
Analysis of immunological markers associated with pregnancy and HIV-1 infection: relevance in perinatal transmission in HIV-1-infected pregnant women with low plasma viral load. Am J Reprod Immunol (2008) 0.81
Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants. Antimicrob Agents Chemother (2006) 0.81
Interleukin-6 and platelet protagonists in T lymphocyte and virological response. Platelets (2005) 0.79
HIV-1 infection is blocked at an early stage in cells devoid of mitochondrial DNA. PLoS One (2013) 0.78
Poor lymphoproliferative responses with low proportion of Gag-specific CD8 TEMRA cells in HIV-1-infected patients showing immunological and virological discordance despite prolonged suppression of plasma viremia. Viral Immunol (2010) 0.78
Low cholesterol? Don't brag yet ... hypocholesterolemia blunts HAART effectiveness: a longitudinal study. J Int AIDS Soc (2010) 0.77
A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation. J Virol (2012) 0.75
Interactions between HIV-1 reverse transcriptase and the downstream template strand in stable complexes with primer-template. PLoS One (2008) 0.75